Article Information
History
- October 3, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Katia J. Bruxvoort, PhD1,2,*,†,
- Bradley Ackerson, MD1,†,
- Lina S. Sy, MPH1,
- Amit Bhavsar, MBBS, MHA3,
- Hung Fu Tseng, PhD1,4,
- Ana Florea, PhD1,
- Yi Luo, PhD1,
- Yun Tian, MS1,
- Zendi Solano, BS1,
- Robyn Widenmaier, MBiotech5,
- Meng Shi, MS5,
- Robbert Van Der Most, PhD6,
- Johannes Eberhard Schmidt, MD, MPH7,
- Jasur Danier, MD5,
- Thomas Breuer, MD, MSc3 and
- Lei Qian, PhD1
- 1Department of Research & Evaluation, Kaiser Permanente Southern California, 100 S Los Robles, Pasadena, CA 91101, USA
- 2Department of Epidemiology, University of Alabama at Birmingham, 1665 University Blvd, Birmingham, AL 35233, USA
- 3GSK, 20 Avenue Fleming, 1300 Wavre, Belgium
- 4Kaiser Permanente Bernard J. Tyson School of Medicine, 98 S. Los Robles Ave., Pasadena, CA 91101, USA
- 5GSK, 14200 Shady Grove Road, Rockville, MD 20850, USA
- 6GSK, 89 Rue de l’Institut, 1330 Rixensart, Belgium
- 7GSK, 1 Via Fiorentina, 53100 Siena, Italy
- ↵*Address for correspondence: Corresponding author: Katia Bruxvoort, PhD MPH, Department of Epidemiology, University of Alabama at Birmingham, 1665 University, Blvd, Birmingham, AL 35233, USA, Phone: 205-975-8625, Email: kbruxvoort{at}uab.edu
↵† KJB and BA contributed equally to this work.
Posted October 03, 2021.
Recombinant adjuvanted zoster vaccine and reduced risk of COVID-19 diagnosis and hospitalization in older adults
